Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma Inc (NQ: LUMO )

4.370 -0.070 (-1.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,594
Open 4.420
Bid (Size) 4.400 (1)
Ask (Size) 4.450 (1)
Prev. Close 4.440
Today's Range 4.360 - 4.490
52wk Range 1.370 - 4.576
Shares Outstanding 8,357,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Analyst Expectations For Lumos Pharma's Future
Via Benzinga

Performance

YTD
+35.71%
+35.71%
1 Month
+19.73%
+19.73%
3 Month
+126.42%
+126.42%
6 Month
+45.67%
+45.67%
1 Year
+25.21%
+25.21%

More News

Read More
INVESTIGATION ALERT: Halper Sadeh LLC Continues to Investigate MMLP, FSHP, ICCH, and LUMO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Lumos Pharma: Q4 Earnings Insights
Via Benzinga
Earnings Preview: Lumos Pharma
Via Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
From Lumos Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
From Lumos Pharma, Inc.
Via GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
Via InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.